PURPOSE: The aim of this study was to analyze the impact of a multidimensional infection control approach on the reduction of ventilator-associated pneumonia (VAP) in intensive care units (ICUs) patients of one hospital in China. MATERIALS AND METHODS: We conducted a before-after study from January 2005 to July 2009, which was divided into baseline (phase 1) and intervention (phase 2) periods. During phase 1, active prospective outcome surveillance of VAP was performed by applying the definitions of the Centers for Disease Control and Prevention/National Health Safety Network, and the methodology of the International Nosocomial Infection Control Consortium. During phase 2, the multidimensional approach was implemented. Ventilator-associated pneumonia rates obtained in phases 1 and 2 were compared in yearly periods. RESULTS: We recorded data from 16,429 patients hospitalized in 3 ICUs, for a total of 74,116 ICU bed days. The VAP baseline rate was 24.1 per 1000 ventilator-days. During phase 2, the VAP rate significantly decreased to 5.7 per 1000 ventilator-days in 2009 (2009 vs 2005: relative risk, 0.31; 95% confidence interval, 0.16-0.36; P = .0001), amounting to a 79% cumulative VAP rate reduction. CONCLUSIONS: Implementing a multidimensional infection control intervention for VAP was associated with a significant cumulative reduction in the VAP rate in our ICUs.
RCT Entities:
PURPOSE: The aim of this study was to analyze the impact of a multidimensional infection control approach on the reduction of ventilator-associated pneumonia (VAP) in intensive care units (ICUs) patients of one hospital in China. MATERIALS AND METHODS: We conducted a before-after study from January 2005 to July 2009, which was divided into baseline (phase 1) and intervention (phase 2) periods. During phase 1, active prospective outcome surveillance of VAP was performed by applying the definitions of the Centers for Disease Control and Prevention/National Health Safety Network, and the methodology of the International Nosocomial Infection Control Consortium. During phase 2, the multidimensional approach was implemented. Ventilator-associated pneumonia rates obtained in phases 1 and 2 were compared in yearly periods. RESULTS: We recorded data from 16,429 patients hospitalized in 3 ICUs, for a total of 74,116 ICU bed days. The VAP baseline rate was 24.1 per 1000 ventilator-days. During phase 2, the VAP rate significantly decreased to 5.7 per 1000 ventilator-days in 2009 (2009 vs 2005: relative risk, 0.31; 95% confidence interval, 0.16-0.36; P = .0001), amounting to a 79% cumulative VAP rate reduction. CONCLUSIONS: Implementing a multidimensional infection control intervention for VAP was associated with a significant cumulative reduction in the VAP rate in our ICUs.
Authors: V D Rosenthal; S K Todi; C Álvarez-Moreno; M Pawar; A Karlekar; A A Zeggwagh; Z Mitrev; F E Udwadia; J A Navoa-Ng; M Chakravarthy; R Salomao; S Sahu; A Dilek; S S Kanj; H Guanche-Garcell; L E Cuéllar; G Ersoz; A Nevzat-Yalcin; N Jaggi; E A Medeiros; G Ye; Ö A Akan; T Mapp; A Castañeda-Sabogal; L Matta-Cortés; F Sirmatel; N Olarte; H Torres-Hernández; N Barahona-Guzmán; R Fernández-Hidalgo; W Villamil-Gómez; D Sztokhamer; S Forciniti; R Berba; H Turgut; C Bin; Y Yang; I Pérez-Serrato; C E Lastra; S Singh; D Ozdemir; S Ulusoy Journal: Infection Date: 2012-06-19 Impact factor: 3.553
Authors: H Leblebicioglu; A N Yalcin; V D Rosenthal; I Koksal; F Sirmatel; S Unal; H Turgut; D Ozdemir; G Ersoz; C Uzun; S Ulusoy; S Esen; F Ulger; A Dilek; H Yilmaz; O Turhan; N Gunay; E Gumus; O Dursun; G Yýlmaz; S Kaya; H Ulusoy; M Cengiz; L Yilmaz; G Yildirim; A Topeli; S Sacar; H Sungurtekin; D Uğurcan; M F Geyik; A Şahin; S Erdogan; A Kaya; N Kuyucu; B Arda; F Bacakoglu Journal: Infection Date: 2013-01-26 Impact factor: 3.553
Authors: Haifaa Hassan Al-Mousa; Abeer Aly Omar; Víctor Daniel Rosenthal; Mona Foda Salama; Nasser Yehia Aly; Mohammad El-Dossoky Noweir; Flavie Maria Rebello; Dennis Malungcot Narciso; Amani Fouad Sayed; Anu Kurian; Sneha Mary George; Amna Mostafa Mohamed; Ruby Jose Ramapurath; Suga Thomas Varghese; Pablo Wenceslao Orellano Journal: J Infect Prev Date: 2018-03-23
Authors: Y Mehta; N Jaggi; V D Rosenthal; C Rodrigues; S K Todi; N Saini; F E Udwadia; A Karlekar; V Kothari; S N Myatra; M Chakravarthy; S Singh; A Dwivedy; N Sen; S Sahu Journal: Epidemiol Infect Date: 2013-03-12 Impact factor: 4.434
Authors: Estuardo Salgado Yepez; Maria M Bovera; Victor D Rosenthal; Hugo A González Flores; Leonardo Pazmiño; Francisco Valencia; Nelly Alquinga; Vanessa Ramirez; Edgar Jara; Miguel Lascano; Veronica Delgado; Cristian Cevallos; Gasdali Santacruz; Cristian Pelaéz; Celso Zaruma; Diego Barahona Pinto Journal: World J Biol Chem Date: 2017-02-26